1-3 of 3
Elizabeth Eisenhauer, MD
Close
Sort by
Journal Articles

Sunitinib in Relapsed or Refractory Diffuse Large B Cell Lymphoma: Results of a Phase II Multi-Center Study of the NCIC Clinical Trials Group.

Rena Buckstein, MD, John Kuruvilla, MD, Neil Chua, MD, Christina Lee, David A Macdonald, MD, Abdulwahab J. Al-Tourah, MD, Alison Foo, Wendy Walsh, S. Percy Ivy, MD, Michael Crump, MD, Elizabeth Eisenhauer, MD
Journal: Blood
Blood (2009) 114 (22): 2729.
https://doi.org/10.1182/blood.V114.22.2729.2729
Published: 2009
Journal Articles

Antitumor Activity of Bortezomib (PS-341; Velcade) in a Phase II Study of Patients with Previously Untreated or Treated Waldenstrom’s Macroglobulinemia (WM).

Christine I. Chen, MD, Darrell White, MD, C. Tom Kouroukis, MD, A. Keith Stewart, MD, Kang Howson-Jan, MD, Loree Larratt, MD, Jean Powers, Elizabeth Eisenhauer, MD
Journal: Blood
Blood (2004) 104 (11): 3278.
https://doi.org/10.1182/blood.V104.11.3278.3278
Published: 2004
Journal Articles

A Phase II Study of ZD6474, a Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Patients with Relapsed Multiple Myeloma (MM).

Michael J. Kovacs, MD, FRCPC, Donna E. Reece, MD, FRCPC, Deborah Marcellus, MD, Ralph M. Meyer, MD, Sarah Matthews, MSc, Rui-Ping Dong, MD, PhD, Elizabeth Eisenhauer, MD, FRCPC
Journal: Blood
Blood (2004) 104 (11): 3464.
https://doi.org/10.1182/blood.V104.11.3464.3464
Published: 2004